Fig. 4: Additional transcriptional biomarkers for pediatric AML. | Nature Communications

Fig. 4: Additional transcriptional biomarkers for pediatric AML.

From: Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia

Fig. 4

a Isolating AMLs that did not have one of the five core fusion alterations, additional cytomolecular subtypes clustered with one another based on LSC47: NPM1, CEBPA, and FLT3 internal tandem duplication (ITD) mutation. b Kaplan–Meier estimates for the probability of EFS within the training cohort for CEBPA, FLT3-ITD, and Other Subtype AMLs. Survival differences were determined using the log-rank test (two-sided and without multiple-testing adjustments). c Notable genes included in LSC47 but not LSC17. Genes are connected to the cytomolecular classes based on whether they contribute to the associated LSC signature and score.

Back to article page